Takeaways From Our Fireside Chat with Oligonucleotide Expert, Dr. Art Levin

Research evidence excerpt

Takeaways From Our Fireside Chat with Oligonucleotide Expert, Dr. Art Levin

June 16, 2026

●Dr. Levin specifically emphasized the growing potential of

oligonucleotide therapeutics in metabolic and cardiovascular

indications (e.g., obesity, fatty liver disease, and hypertension),

neurological disorders, particularly rare diseases, and oncology.

Ultimately, he suggested that oligonucleotides may be applicable

across a broad range of genetically driven diseases.

●While oligonucleotides offer considerable promise as a therapeutic

modality, we learned that current synthesis and manufacturing

technologies represent a critical constraint, limiting the ability to scale

production for larger indications.

●Current methods for oligonucleotide are time-consuming, require vast

amounts of resources (reaction materials), produce toxic waste and are

inefficient when scaled from smaller to larger production levels.

What Does this Mean for Codexis? How is Codexis differentiated?

●As the need for more efficient synthesis methods is needed, Codexis

is competitively positioned with its ECO Synthesis Manufacturing

Platform.

●Specifically Codexis' platform utilizes enzymes to synthesize

oligonucleotides which is more efficient, faster and produces less

waste than traditional methods.

●For example, conventional oligonucleotide synthesis requires four

separate chemical reactions to incorporate a single nucleotide, with

efficiency declining as oligonucleotide length increases, leading to

substantial waste generation.

●In contrast, Codexis' ECO Synthesis enzymatic platform requires

fewer reaction steps, reducing waste while improving manufacturing

speed and efficiency.

●Another additional benefit the ECO Synthesis offers is stereochemical